Close

elicited

Serum neutralising activity against SARS-CoV-2 variants elicited by CoronaVac

Emergence of multiple SARS-CoV-2 variants of concern (VOCs) harbouring mutations in the spike protein—the major target of neutralising antibodies—has raised serious concerns about the potential for reduced protective efficacy of humoral responses elicited by vaccination. CoronaVac (Sinovac Biotech, Beijing, China) is an inactivated vaccine that has been authorised for conditional […]

Read More